As PIKfyve inhibition is now being clinically evaluated for efficacy against COVID-19,59,101 our results substantiate the broad potential of PIKfyve inhibition as a DC-enhancing strategy across disease states. The gene discussed is PIKFYVE; the disease is COVID-19.